company background image
EIGR

Eiger BioPharmaceuticals NasdaqGM:EIGR Stock Report

Last Price

US$4.54

Market Cap

US$200.1m

7D

10.5%

1Y

-21.3%

Updated

01 Dec, 2022

Data

Company Financials +
EIGR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EIGR Stock Overview

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.

Eiger BioPharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eiger BioPharmaceuticals
Historical stock prices
Current Share PriceUS$4.54
52 Week HighUS$10.02
52 Week LowUS$3.53
Beta1.43
1 Month Change-11.16%
3 Month Change-47.51%
1 Year Change-21.32%
3 Year Change-65.66%
5 Year Change-61.69%
Change since IPO-71.43%

Recent News & Updates

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Recent updates

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Mar 15
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Does Eiger BioPharmaceuticals (NASDAQ:EIGR) Have A Healthy Balance Sheet?

Jun 03
Does Eiger BioPharmaceuticals (NASDAQ:EIGR) Have A Healthy Balance Sheet?

Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares This Year?

Mar 16
Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares This Year?

What Type Of Shareholders Own The Most Number of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Jan 22
What Type Of Shareholders Own The Most Number of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Dec 01
Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

Shareholder Returns

EIGRUS BiotechsUS Market
7D10.5%2.3%1.5%
1Y-21.3%-10.2%-14.8%

Return vs Industry: EIGR underperformed the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: EIGR underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is EIGR's price volatile compared to industry and market?
EIGR volatility
EIGR Average Weekly Movement12.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: EIGR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: EIGR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200854David Coryhttps://www.eigerbio.com

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.

Eiger BioPharmaceuticals, Inc. Fundamentals Summary

How do Eiger BioPharmaceuticals's earnings and revenue compare to its market cap?
EIGR fundamental statistics
Market CapUS$200.10m
Earnings (TTM)-US$93.41m
Revenue (TTM)US$14.15m

14.1x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EIGR income statement (TTM)
RevenueUS$14.15m
Cost of RevenueUS$1.60m
Gross ProfitUS$12.55m
Other ExpensesUS$105.96m
Earnings-US$93.41m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.12
Gross Margin88.72%
Net Profit Margin-660.21%
Debt/Equity Ratio50.2%

How did EIGR perform over the long term?

See historical performance and comparison